HDAC3 regulates stability of estrogen receptor α mRNA

Biochemical and Biophysical Research Communications

Volumn 432, Issue 2, 2013, Pages 236-241

  Oie, Shohei ^a   Matsuzaki, Kazuya ^a   Yokoyama, Wataru ^a   Murayama, Akiko ^a   Yanagisawa, Junn ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Breast cancer; Cell proliferation; ER ; HDAC inhibitor; HDAC3; MRNA stability

Indexed keywords

APICIDIN; ENTINOSTAT; ESTROGEN RECEPTOR ALPHA; HISTONE DEACETYLASE 3; MESSENGER RNA; TRICHOSTATIN A;

ARTICLE; BREAST CANCER; CANCER CELL; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME REGULATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

BREAST NEOPLASMS; CELL LINE, TUMOR; ESTROGEN RECEPTOR ALPHA; FEMALE; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; RNA STABILITY; RNA, MESSENGER;

EID: 84875262747     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.02.007     Document Type: Article

References (23)

1. Linares A., Dalenc F., Balaguer P., Boulle N., Cavailles V. Manipulating protein acetylation in breast cancer: a promising approach in combination with hormonal therapies?. J. Biomed. Biotechnol. 2011, 2011:856985.
2. Sharma D., Blum J., Yang X., Beaulieu N., Macleod A.R., Davidson N.E. Release of methyl CpG binding proteins and histone deacetylase 1 from the estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells. Mol. Endocrinol. 2005, 19:1740-1751.
3. Liu X.F., Bagchi M.K. Recruitment of distinct chromatin-modifying complexes by tamoxifen-complexed estrogen receptor at natural target gene promoters in vivo. J. Biol. Chem. 2004, 279:15050-15058.
4. Metivier R., Penot G., Hubner M.R., Reid G., Brand H., Kos M., Gannon F. Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 2003, 115:751-763.
5. Witt O., Deubzer H.E., Milde T., Oehme I. HDAC family: what are the cancer relevant targets?. Cancer Lett. 2009, 277:8-21.
6. Marks P., Rifkind R.A., Richon V.M., Breslow R., Miller T., Kelly W.K. Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 2001, 1:194-202.
7. Bicaku E., Marchion D.C., Schmitt M.L., Munster P.N. Selective inhibition of histone deacetylase 2 silences progesterone receptor-mediated signaling. Cancer Res. 2008, 68:1513-1519.
8. deFazio A., Chiew Y.E., Donoghue C., Lee C.S., Sutherland R.L. Effect of sodium butyrate on estrogen receptor and epidermal growth factor receptor gene expression in human breast cancer cell lines. J. Biol. Chem. 1992, 267:18008-18012.
9. Margueron R., Duong V., Bonnet S., Escande A., Vignon F., Balaguer P., Cavailles V. Histone deacetylase inhibition and estrogen receptor alpha levels modulate the transcriptional activity of partial antiestrogens. J. Mol. Endocrinol. 2004, 32:583-594.
10. Jang E.R., Lim S.J., Lee E.S., Jeong G., Kim T.Y., Bang Y.J., Lee J.S. The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen. Oncogene 2004, 23:1724-1736.
11. Alao J.P., Lam E.W., Ali S., Buluwela L., Bordogna W., Lockey P., Varshochi R., Stavropoulou A.V., Coombes R.C., Vigushin D.M. Histone deacetylase inhibitor trichostatin A represses estrogen receptor alpha-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines. Clin. Cancer Res. 2004, 10:8094-8104.
12. Lu X., Lu X., Wang Z.C., Iglehart J.D., Zhang X., Richardson A.L. Predicting features of breast cancer with gene expression patterns. Breast Cancer Res. Treat. 2008, 108:191-201.
13. Pryzbylkowski P., Obajimi O., Keen J.C. Trichostatin A and 5 Aza-2' deoxycytidine decrease estrogen receptor mRNA stability in ER positive MCF7 cells through modulation of HuR. Breast Cancer Res. Treat. 2008, 111:15-25.
14. Reid G., Denger S., Kos M., Gannon F. Human estrogen receptor-alpha: regulation by synthesis, modification and degradation. Cell. Mol. Life Sci. 2002, 59:821-831.
15. Khan N., Jeffers M., Kumar S., Hackett C., Boldog F., Khramtsov N., Qian X., Mills E., Berghs S.C., Carey N., Finn P.W., Collins L.S., Tumber A., Ritchie J.W., Jensen P.B., Lichenstein H.S., Sehested M. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem. J. 2008, 409:581-589.
16. Denkert C., Weichert W., Winzer K.J., Muller B.M., Noske A., Niesporek S., Kristiansen G., Guski H., Dietel M., Hauptmann S. Expression of the ELAV-like protein HuR is associated with higher tumor grade and increased cyclooxygenase-2 expression in human breast carcinoma. Clin. Cancer Res. 2004, 10:5580-5586.
17. Heinonen M., Bono P., Narko K., Chang S.H., Lundin J., Joensuu H., Furneaux H., Hla T., Haglund C., Ristimaki A. Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma. Cancer Res. 2005, 65:2157-2161.
18. Sommer S., Cui Y., Brewer G., Fuqua S.A. The c-Yes 3'-UTR contains adenine/uridine-rich elements that bind AUF1 and HuR involved in mRNA decay in breast cancer cells. J. Steroid Biochem. Mol. Biol. 2005, 97:219-229.
19. Watts C.K., Sweeney K.J., Warlters A., Musgrove E.A., Sutherland R.L. Antiestrogen regulation of cell cycle progression and cyclin D1 gene expression in MCF-7 human breast cancer cells. Breast Cancer Res. Treat. 1994, 31:95-105.
20. Kenealy M.-R., Flouriot G., Sonntag-Buck V., Dandekar T., Brand H., Gannon F. The 3'-untranslated region of the human estrogen receptor-agene mediates rapid messenger ribonucleic acid turnover. Endocrinology 2000, 141:2805-2813.
21. Wilson A.J., Byun D.S., Popova N., Murray L.B., L'Italien K., Sowa Y., Arango D., Velcich A., Augenlicht L.H., Mariadason J.M. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J. Biol. Chem. 2006, 281:13548-13558.
22. Bhaskara S., Chyla B.J., Amann J.M., Knutson S.K., Cortez D., Sun Z.W., Hiebert S.W. Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control. Mol. Cell 2008, 30:61-72.
23. Karagianni P., Wong J. HDAC3: taking the SMRT-N-CoRrect road to repression. Oncogene 2007, 26:5439-5449.